Star51 Capital announced the first close of its inaugural venture fund, establishing an operator-led investment platform focused on companies at the intersection of medical technology and artificial intelligence. The fund’s first close was anchored by Abbott and Mayo Clinic, with additional participation from senior Medtech executives, physicians, life sciences professionals, and the firm’s general and operating partners.

The fund will invest in early and growth-stage companies across interventional therapies, diagnostics, monitoring, and healthcare digitalization, sourcing opportunities from the United States, Europe, and the Middle East.

Star51 Capital was founded by Adam Rosenwach and Tal Wenderow. Rosenwach previously held senior operating and finance roles at Medtech incubators and high-growth startups, including Coridea and Deerfield Catalyst. Wenderow founded Corindus Vascular Robotics and later guided the company to its $1.1 billion acquisition by Siemens Healthineers before serving as a venture partner for a global Medtech strategic investor.

The leadership team also includes Operating Partners Raymond W. Cohen, Scott Pantel, and Joe Mullings. Collectively, the team brings decades of experience founding, operating, and exiting Medtech companies and will provide portfolio companies with support spanning clinical, commercial, regulatory, and intellectual property disciplines.

Star51 describes itself as an “ecosystem fund” designed to combine strategic capital with operator networks to help portfolio companies navigate clinical validation, regulatory clearance, commercialization, and scaling. The firm also utilizes its proprietary AI platform, StarVision™, to support its investment activities.

According to the company, the participation of industry operators as limited partners aligns their interests with portfolio outcomes while providing founders with access to expertise and strategic relationships intended to accelerate growth and clinical adoption.

KEY QUOTES:

“Medtech is at an inflection point. Technology advancements and AI are reshaping how devices are designed, delivered, and personalized. That transformation is happening now. The companies that will help define the next era of Medtech are being built today. We believe that the time to support them with capital and the right operational expertise is now.”

Tal Wenderow, Founding Managing Partner, Star51 Capital

“Star51 is not a traditional venture fund. It’s an ecosystem built by operators, for operators. What sets Star51 apart is the caliber of our ecosystem: leading strategic investors, operating partners who have built and scaled category-defining companies, and a network that gives founders the clinical insight, commercial access, and strategic relationships they need to grow and scale.”

Adam Rosenwach, Founding Managing Partner, Star51 Capital